Ireland· IE-PA-EU/1/97/055/002
Viramune 50 mg/5 mL oral suspension
A nevirapine product containing nevirapine hemihydrate, registered in Ireland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 16 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Nevirapine is registered in 16 of 19 countries.
Countries holding a registration under ATC J05AG01 (nevirapine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Nevirapine · ATC J05AG01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nevirapine costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $3.81 in France to $7.77 in Switzerland — a ×2.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nevirapine · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.77
- FR France$3.81
The record
At a glance
HPRA (Ireland)- Active substance
- Nevirapine hemihydrate
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Ireland (IE)
- ATC code
- J05AG01
- ATC class
- Nevirapine
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/97/055/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
316 interactions on record for nevirapine.
Graded by severity as the source publishes them — 26 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nevirapine · interactions on record
316 records
- 26 severe
- 220 moderate
- 8 minor
- 49 info
Most severe, free to view
- DeflazacortH02AB13severe
- BrigatinibL01ED04severe
- LorlatinibL01ED05severe
- CobimetinibL01EE02severe
13 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nevirapine in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2e007847-21cc-441b-9b0c-d981a85a1e46 GET /v1/drugs/2e007847-21cc-441b-9b0c-d981a85a1e46?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral suspension",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"J05AG",
"J05AG01"
],
"strength": null,
"pa_number": "EU/1/97/055/002",
"substances": [
"Nevirapine hemihydrate"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "18/06/1999",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about nevirapine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.